Vogenx, Inc. (VOGX) received an initial ownership report on Form 3 for Chief Executive Officer and director James Green, who is also a ten percent owner. The filing shows indirect ownership of 1,800,000 shares of Common Stock held through Osprey Investments I LLC, where James Green and Melissa Green are members and share voting and dispositive power. In addition, James Green holds stock options directly: one option with an exercise price of $1.03 per share for 116,666 shares of Common Stock, fully vested and exercisable, expiring on July 27, 2027; and a second option with an exercise price of $1.26 per share for 26,666 shares, expiring on January 1, 2031, which vests in three annual tranches in 2026, 2027, and 2028, subject to his continued service.
Vogenx, Inc. (VOGX), a clinical-stage biopharma focused on metabolic diseases such as post-bariatric hypoglycemia (PBH) and gastroparesis, is pursuing an initial public offering of 6,250,000 shares of common stock at an expected price range of $11.00–$13.00 per share, with an application to list on the Nasdaq Capital Market under the symbol VOGX. The company is advancing its lead SGLT1 inhibitor, mizagliflozin, now in Phase 2b preparation for PBH and planning Phase 2 trials in gastroparesis and GIP-dependent Cushing’s Syndrome.
Assuming a $12.00 midpoint price, Vogenx estimates net IPO proceeds of about $67.8 million (or $78.2 million with full underwriter option), boosting pro forma cash to roughly $68.0 million and stockholders’ equity to about $67.1 million. Funds are earmarked primarily for continued development of mizagliflozin, other R&D, and general corporate purposes. Vogenx is an emerging growth company and smaller reporting company, with no revenue to date and net losses of $2.2 million in 2024, $1.4 million in 2025, and $0.5 million in the first quarter of 2026.